Developer docs
API playgroundTry for free, no card

Search company profiles

Cofactor Genomics

Full company profile

uuid0000xgz

Namestring
Cofactor Genomics
Legal namestring
Cofactor Genomics, Inc.
Company typeenum
Private
Founded yearint
2008
Descriptiontext

Cofactor Genomics is a commercial-stage molecular diagnostics company that builds RNA-based predictive tests to match cancer patients to immunotherapy. Its flagship product, OncoPrism, uses multidimensional biomarkers derived from tumor RNA sequencing combined with proprietary machine learning models (Health Expression Models and Predictive Immune Modeling) to predict patient response to immune checkpoint inhibitors — addressing the well-documented failure mode of PD-L1 IHC, where a large majority of treated patients do not benefit. Validated indications include non-small cell lung cancer (OncoPrism-NSCLC) and head and neck squamous cell carcinoma (OncoPrism-HNSCC), with a diagnostic pipeline covering 11 solid tumor cancers.

The underlying technology is anchored by the PREDAPT clinical trial (NCT04510129), which enrolled patients across 24+ U.S. healthcare systems and generated the roughly 1,500-sample dataset that trains the company's Predictive Immune Modeling platform. The company operates a CAP-accredited clinical laboratory in St. Louis, holds HIPAA-covered clinical operations, and is headquartered in San Francisco as a Delaware C-corp. Cofactor also offers research-use products (ImmunoPrism assay, ActiveSite bioinformatics platform, spike-in RNA controls) that generate adjacent revenue and reinforce the clinical product.

Cofactor makes money by performing OncoPrism tests in its CAP-certified laboratory, with samples shipped from ordering oncologists and pathologists at partner health systems. Medicare national coverage from Palmetto GBA was obtained in October 2024, enabling direct Medicare billing and materially expanding the addressable patient population. The December 2025 strategic investment from Labcorp and Ascension Ventures is earmarked to accelerate commercial rollout across U.S. cancer care networks. Go-to-market is enterprise-focused, targeting medical oncologists, pathologists, and healthcare systems, supported by named institutional partners including Mayo Clinic, Cleveland Clinic, Stanford, Johns Hopkins, and Intermountain Health.

Short descriptiontext

Cofactor Genomics is a commercial-stage molecular diagnostics company that uses RNA sequencing and proprietary machine learning to predict cancer patient response to immunotherapy, serving oncologists, pathologists, and healthcare systems through its CAP-accredited OncoPrism test.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSaint Louis, United States
HQ citystring
Saint Louis
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
RNA-based diagnostics, immunotherapy response prediction, precision medicine biomarkers, clinical diagnostic laboratory, RNA sequencing services
Industry7 codes
PRIMARYHLAFAMAE
Molecular Diagnostics & Genomics Laboratories
SECONDARYHLAAAMAJ
Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAHAAAD
Molecular Diagnostics (PCR/NAAT/NGS-based IVD)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAALAD
Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics)
SECONDARYHLACAMAJ
Pathology Reporting, Synoptic Templates & Cancer Registry Interfaces
Healthcare & Life Sciences/Digital Health & Health IT/Laboratory Information Systems (LIS/LIMS) & Pathology Informatics
SECONDARYHLAGADAF
Molecular & Genetic Testing (PCR/NGS/qPCR)
NAICS code4 codes
  • Medical Laboratories621511
  • Medical and Diagnostic Laboratories6215
  • Medical and Diagnostic Laboratories62151
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Services-Medical Laboratories8071
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Clinical Molecular Diagnostics
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Diagnostic Laboratory Services
TypeProfessional Services
Description

Cofactor Genomics operates a CAP-certified clinical diagnostic laboratory offering OncoPrism and ImmunoPrism tests. Revenue is generated through diagnostic testing services billed to healthcare providers, hospitals, and insurance companies including Medicare (Palmetto GBA national coverage). The company disclosed Medicare coverage for OncoPrism as a key milestone enabling broader commercial adoption.

cofactorgenomics.com
2Clinical Trial Services
TypeProfessional Services
Description

The company conducts sponsored clinical trials and research studies with healthcare system partners. The PREDAPT trial (NCT04510129) involves partnerships with 24 healthcare systems studying 11 solid tumor cancers. This provides clinical validation data while building relationships with potential commercial customers.

cofactorgenomics.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 5 records shown
1OncoPrism
Description

RNA-based predictive diagnostic platform for predicting immunotherapy response in cancer patients

cofactorgenomics.com
+4 more records
Core offering1 text field

Cofactor Genomics operates a CAP-certified clinical diagnostic laboratory that performs RNA-based predictive diagnostic tests, principally the OncoPrism family (OncoPrism-NSCLC and OncoPrism-HNSCC), which use multidimensional biomarkers and machine learning to predict cancer patient response to immunotherapy before treatment decisions. The company's offering is anchored by a proprietary Health Expression Models database of immune cell gene expression profiles and validated through the PREDAPT clinical trial across 11 solid tumor indications with 24+ healthcare system partners.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Cofactor Genomics is a commercial-stage RNA-based predictive diagnostics company. The core product is the OncoPrism® family of tests, which use multidimensional RNA biomarkers and machine learning to predict cancer patient response to immunotherapy. OncoPrism-NSCLC and OncoPrism-HNSCC are specific cancer-type validated tests. Supporting the clinical diagnostics is the research-use ImmunoPrism™ assay for immune profiling. The company also provides RNA-seq services with bioinformatics through the ActiveSite platform, built on a database of Health Expression Models. The PREDAPT clinical trial validates the platform across 11 solid tumor cancers.

Product and service3 records
1OncoPrism Immunotherapy Diagnostic
CategoryClinical Molecular Diagnostics
Description

RNA-based predictive diagnostic test that uses multidimensional biomarkers and machine learning to predict cancer patient response to immunotherapy before treatment. Indication-specific validated sub-tests include OncoPrism-NSCLC for non-small cell lung cancer and OncoPrism-HNSCC for head and neck squamous cell carcinoma, with a pipeline covering 11 solid tumor indications. Performed in Cofactor's CAP-certified clinical diagnostic laboratory with results returned to ordering physicians, supported by Medicare national coverage.

2ImmunoPrism Research Use Assay
CategoryResearch Assay / Immune Profiling
Description

RNA-based immune profiling assay that estimates the abundance of eight immune cell types, measures expression of immune-relevant genes such as PD-1 and CTLA-4, and uses Predictive Immune Modeling to classify patients. Available as Research Use Only or as a CAP-validated assay for research applications in immuno-oncology.

3ActiveSite Bioinformatics Platform
CategoryBioinformatics Software Platform
Description

Web-based bioinformatics interface providing project tracking, quality metrics, and data discovery for RNA sequencing projects. Includes saturation curves for every sample showing performance, gene expression levels, and outlier identification, with automated reporting on sequencing depth requirements and questionable samples to exclude from comparison.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
1Culmination Bio
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-05-09
Description

Partnership with Intermountain Health spinout Culmination Bio to leverage samples and data from one of the largest biobanks in the country to fuel development of OncoPrism test in 11 cancers. Cofactor is 'moving aggressively' to advance the test with Culmination Bio's extensive biobank resources.

224 Healthcare Systems (PREDAPT Trial)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

National PREDAPT (Predicting Immunotherapy Efficacy From Analysis of Pre-treatment Tumor Biopsies) Trial (NCT04510129) evaluating OncoPrism assay with 24+ healthcare system partners studying 11 solid tumor cancers.

cofactorgenomics.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partner healthcare system in PREDAPT clinical trial and collaboration with spinout Culmination Bio leveraging extensive biobank samples and data for precision medicine clinical trial.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Listed as a client and partner working with Cofactor on clinical validation of OncoPrism diagnostics.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Listed as a client and partner working with Cofactor on clinical validation of OncoPrism diagnostics.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Academic medical center partner listed as working with Cofactor on clinical validation activities.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Academic medical center partner listed as working with Cofactor on clinical validation activities.

8UC San Diego
Strategic tierMajorTypeStrategic or Co-development Partner
Description

Academic medical center partner listed as working with Cofactor on clinical validation activities.

cofactorgenomics.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Oncocyte
TypeDirect peer
Description

Commercial-stage molecular diagnostics company developing tests to inform immunotherapy treatment decisions (e.g., DetermaIO), making it the most directly comparable peer to Cofactor's OncoPrism in the RNA-based IO response prediction space.

TypeDirect peer
Description

Cancer genomics company offering NeXT Personal, an ultra-sensitive tumor-informed liquid biopsy and molecular profiling assay. Comparable NGS-based oncology diagnostics player with similar business model of selling molecular tests to oncologists and pharma partners.

TypeDirect peer
Description

Molecular profiling company offering MI Profile and other comprehensive tumor profiling tests that inform treatment selection, including for immunotherapy. Directly comparable as a comprehensive RNA/DNA-based molecular diagnostic platform for oncology treatment guidance.

TypeDirect peer
Description

RNA-based spatial biology and gene expression company with GeoMx Digital Spatial Profiling and nCounter platforms — directly comparable to Cofactor in RNA-based immune profiling technology and immuno-oncology biomarker development.

TypeDirect peer
Description

Immune profiling company leveraging sequencing and ML to characterize immune responses, with clonoSEQ for MRD and immunoSEQ for immune repertoire. Comparable in applying sequencing + machine learning to immune-related oncology diagnostics.

TypeBroad incumbent
Description

Leading liquid biopsy and oncology precision medicine company offering Guardant360 and Reveal tests. Broader incumbent in oncology molecular diagnostics with much larger commercial footprint, overlapping in immuno-oncology patient stratification.

TypeBroad incumbent
Description

Comprehensive genomic profiling leader (FoundationOne CDx, FoundationOne Liquid CDx) used to guide targeted and immunotherapy treatment selection. Large incumbent with established oncology relationships overlapping with OncoPrism's use case.

TypeBroad incumbent
Description

Oncology and reproductive health diagnostics company with Signatera MRD test and growing oncology franchise. Comparable in commercial-stage molecular diagnostics sold to oncologists through similar reimbursement-driven channels.

TypeBroad incumbent
Description

Oncology-focused reference laboratory providing comprehensive molecular and biomarker testing services to community oncologists. Comparable business model as a CAP-certified oncology diagnostic lab with established hospital and oncologist relationships.

TypeBroad incumbent
Description

Large-scale molecular diagnostics company with Oncotype DX and growing oncology franchise (OncoExTra, Cologuard). Comparable as an established molecular diagnostics company pursuing multi-indication oncology testing with Medicare reimbursement.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers8 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors18 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cofactor Genomics

Clinical Molecular Diagnosticscofactorgenomics.com

Cofactor Genomics is a commercial-stage molecular diagnostics company that uses RNA sequencing and proprietary machine learning to predict cancer patient response to immunotherapy, serving oncologists, pathologists, and healthcare systems through its CAP-accredited OncoPrism test.

What Cofactor Genomics does

Cofactor Genomics is a commercial-stage molecular diagnostics company that builds RNA-based predictive tests to match cancer patients to immunotherapy. Its flagship product, OncoPrism, uses multidimensional biomarkers derived from tumor RNA sequencing combined with proprietary machine learning models (Health Expression Models and Predictive Immune Modeling) to predict patient response to immune checkpoint inhibitors — addressing the well-documented failure mode of PD-L1 IHC, where a large majority of treated patients do not benefit. Validated indications include non-small cell lung cancer (OncoPrism-NSCLC) and head and neck squamous cell carcinoma (OncoPrism-HNSCC), with a diagnostic pipeline covering 11 solid tumor cancers.

The underlying technology is anchored by the PREDAPT clinical trial (NCT04510129), which enrolled patients across 24+ U.S. healthcare systems and generated the roughly 1,500-sample dataset that trains the company's Predictive Immune Modeling platform. The company operates a CAP-accredited clinical laboratory in St. Louis, holds HIPAA-covered clinical operations, and is headquartered in San Francisco as a Delaware C-corp. Cofactor also offers research-use products (ImmunoPrism assay, ActiveSite bioinformatics platform, spike-in RNA controls) that generate adjacent revenue and reinforce the clinical product.

Cofactor makes money by performing OncoPrism tests in its CAP-certified laboratory, with samples shipped from ordering oncologists and pathologists at partner health systems. Medicare national coverage from Palmetto GBA was obtained in October 2024, enabling direct Medicare billing and materially expanding the addressable patient population. The December 2025 strategic investment from Labcorp and Ascension Ventures is earmarked to accelerate commercial rollout across U.S. cancer care networks. Go-to-market is enterprise-focused, targeting medical oncologists, pathologists, and healthcare systems, supported by named institutional partners including Mayo Clinic, Cleveland Clinic, Stanford, Johns Hopkins, and Intermountain Health.

Cofactor Genomics firmographics

Firmographics
Name
Cofactor Genomics
Legal name
Cofactor Genomics, Inc.
Website
https://cofactorgenomics.com
Company type
Private
Founded year
2008
Operating status
Operating
Headcount range
11–50 employees
Short description
Cofactor Genomics is a commercial-stage molecular diagnostics company that uses RNA sequencing and proprietary machine learning to predict cancer patient response to immunotherapy, serving oncologists, pathologists, and healthcare systems through its CAP-accredited OncoPrism test.
Ownership category
akta.pro rank

Cofactor Genomics industry classification

Industry
Product category
Clinical Molecular Diagnostics
NAICS
Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215), Medical and Diagnostic Laboratories (62151), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAFAMAE
Molecular Diagnostics & Genomics Laboratories
SECONDARYHLAAAMAJ
Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAHAAAD
Molecular Diagnostics (PCR/NAAT/NGS-based IVD)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAALAD
Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics)
SECONDARYHLACAMAJ
Pathology Reporting, Synoptic Templates & Cancer Registry Interfaces
Healthcare & Life Sciences/Digital Health & Health IT/Laboratory Information Systems (LIS/LIMS) & Pathology Informatics
SECONDARYHLAGADAF
Molecular & Genetic Testing (PCR/NGS/qPCR)

Keywords

  • RNA-based diagnostics
  • Immunotherapy response prediction
  • Precision medicine biomarkers
  • Clinical diagnostic laboratory
  • RNA sequencing services

Where Cofactor Genomics is headquartered

Location

Headquarters

HQ city
Saint Louis
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Cofactor Genomics business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

  1. Diagnostic Laboratory Services: Cofactor Genomics operates a CAP-certified clinical diagnostic laboratory offering OncoPrism and ImmunoPrism tests. Revenue is generated through diagnostic testing services billed to healthcare providers, hospitals, and insurance companies including Medicare (Palmetto GBA national coverage). The company disclosed Medicare coverage for OncoPrism as a key milestone enabling broader commercial adoption.
  2. Clinical Trial Services: The company conducts sponsored clinical trials and research studies with healthcare system partners. The PREDAPT trial (NCT04510129) involves partnerships with 24 healthcare systems studying 11 solid tumor cancers. This provides clinical validation data while building relationships with potential commercial customers.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels6 records

Cofactor Genomics product offering

Product offering

Core offering

Cofactor Genomics operates a CAP-certified clinical diagnostic laboratory that performs RNA-based predictive diagnostic tests, principally the OncoPrism family (OncoPrism-NSCLC and OncoPrism-HNSCC), which use multidimensional biomarkers and machine learning to predict cancer patient response to immunotherapy before treatment decisions. The company's offering is anchored by a proprietary Health Expression Models database of immune cell gene expression profiles and validated through the PREDAPT clinical trial across 11 solid tumor indications with 24+ healthcare system partners.

Product overview

Cofactor Genomics is a commercial-stage RNA-based predictive diagnostics company. The core product is the OncoPrism® family of tests, which use multidimensional RNA biomarkers and machine learning to predict cancer patient response to immunotherapy. OncoPrism-NSCLC and OncoPrism-HNSCC are specific cancer-type validated tests. Supporting the clinical diagnostics is the research-use ImmunoPrism™ assay for immune profiling. The company also provides RNA-seq services with bioinformatics through the ActiveSite platform, built on a database of Health Expression Models. The PREDAPT clinical trial validates the platform across 11 solid tumor cancers.

Differentiator

Problem solved

Functional benefit

Brands

  • OncoPrism: RNA-based predictive diagnostic platform for predicting immunotherapy response in cancer patients
  • OncoPrism-NSCLC
  • OncoPrism-HNSCC
  • ActiveSite
  • ImmunoPrism

Products and services

  • OncoPrism Immunotherapy Diagnostic RNA-based predictive diagnostic test that uses multidimensional biomarkers and machine learning to predict cancer patient response to immunotherapy before treatment. Indication-specific validated sub-tests include OncoPrism-NSCLC for non-small cell lung cancer and OncoPrism-HNSCC for head and neck squamous cell carcinoma, with a pipeline covering 11 solid tumor indications. Performed in Cofactor's CAP-certified clinical diagnostic laboratory with results returned to ordering physicians, supported by Medicare national coverage.
  • ImmunoPrism Research Use Assay RNA-based immune profiling assay that estimates the abundance of eight immune cell types, measures expression of immune-relevant genes such as PD-1 and CTLA-4, and uses Predictive Immune Modeling to classify patients. Available as Research Use Only or as a CAP-validated assay for research applications in immuno-oncology.
  • ActiveSite Bioinformatics Platform Web-based bioinformatics interface providing project tracking, quality metrics, and data discovery for RNA sequencing projects. Includes saturation curves for every sample showing performance, gene expression levels, and outlier identification, with automated reporting on sequencing depth requirements and questionable samples to exclude from comparison.

Companies that use Cofactor Genomics

Customer profile

Named customers8 records

Segments3 records

Ideal customer profiles3 records

Cofactor Genomics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature8 records

Cofactor Genomics partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core and major.

  • Culmination BiocoreStrategic or Co-development Partner · 9 May 2023Partnership with Intermountain Health spinout Culmination Bio to leverage samples and data from one of the largest biobanks in the country to fuel development of OncoPrism test in 11 cancers. Cofactor is 'moving aggressively' to advance the test with Culmination Bio's extensive biobank resources.
  • 24 Healthcare Systems (PREDAPT Trial)coreStrategic or Co-development PartnerNational PREDAPT (Predicting Immunotherapy Efficacy From Analysis of Pre-treatment Tumor Biopsies) Trial (NCT04510129) evaluating OncoPrism assay with 24+ healthcare system partners studying 11 solid tumor cancers.
  • Intermountain HealthcoreStrategic or Co-development PartnerPartner healthcare system in PREDAPT clinical trial and collaboration with spinout Culmination Bio leveraging extensive biobank samples and data for precision medicine clinical trial.
  • Cleveland ClinicmajorStrategic or Co-development PartnerListed as a client and partner working with Cofactor on clinical validation of OncoPrism diagnostics.
  • Mayo ClinicmajorStrategic or Co-development PartnerListed as a client and partner working with Cofactor on clinical validation of OncoPrism diagnostics.
  • Stanford UniversitymajorStrategic or Co-development PartnerAcademic medical center partner listed as working with Cofactor on clinical validation activities.
  • Johns Hopkins UniversitymajorStrategic or Co-development PartnerAcademic medical center partner listed as working with Cofactor on clinical validation activities.
  • UC San DiegomajorStrategic or Co-development PartnerAcademic medical center partner listed as working with Cofactor on clinical validation activities.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Cofactor Genomics competitors and assessment

Company assessment

Direct peers

  • Oncocyte: Commercial-stage molecular diagnostics company developing tests to inform immunotherapy treatment decisions (e.g., DetermaIO), making it the most directly comparable peer to Cofactor's OncoPrism in the RNA-based IO response prediction space.
  • Personalis: Cancer genomics company offering NeXT Personal, an ultra-sensitive tumor-informed liquid biopsy and molecular profiling assay. Comparable NGS-based oncology diagnostics player with similar business model of selling molecular tests to oncologists and pharma partners.
  • Caris Life Sciences: Molecular profiling company offering MI Profile and other comprehensive tumor profiling tests that inform treatment selection, including for immunotherapy. Directly comparable as a comprehensive RNA/DNA-based molecular diagnostic platform for oncology treatment guidance.
  • NanoString Technologies (Bruker): RNA-based spatial biology and gene expression company with GeoMx Digital Spatial Profiling and nCounter platforms — directly comparable to Cofactor in RNA-based immune profiling technology and immuno-oncology biomarker development.
  • Adaptive Biotechnologies: Immune profiling company leveraging sequencing and ML to characterize immune responses, with clonoSEQ for MRD and immunoSEQ for immune repertoire. Comparable in applying sequencing + machine learning to immune-related oncology diagnostics.

Broad incumbents

  • Guardant Health: Leading liquid biopsy and oncology precision medicine company offering Guardant360 and Reveal tests. Broader incumbent in oncology molecular diagnostics with much larger commercial footprint, overlapping in immuno-oncology patient stratification.
  • Foundation Medicine (Roche): Comprehensive genomic profiling leader (FoundationOne CDx, FoundationOne Liquid CDx) used to guide targeted and immunotherapy treatment selection. Large incumbent with established oncology relationships overlapping with OncoPrism's use case.
  • Natera: Oncology and reproductive health diagnostics company with Signatera MRD test and growing oncology franchise. Comparable in commercial-stage molecular diagnostics sold to oncologists through similar reimbursement-driven channels.
  • NeoGenomics: Oncology-focused reference laboratory providing comprehensive molecular and biomarker testing services to community oncologists. Comparable business model as a CAP-certified oncology diagnostic lab with established hospital and oncologist relationships.
  • Exact Sciences: Large-scale molecular diagnostics company with Oncotype DX and growing oncology franchise (OncoExTra, Cologuard). Comparable as an established molecular diagnostics company pursuing multi-indication oncology testing with Medicare reimbursement.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Cofactor Genomics social profiles

Digital presence

Cofactor Genomics compliance and trust

Trust signal

Compliance2 records

Cofactor Genomics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cofactor Genomics leadership team

Management profile

Number of profiles

Profiles8 records

Cofactor Genomics funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors18 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cofactor Genomics M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cofactor Genomics

What does Cofactor Genomics do?

Cofactor Genomics operates a CAP-certified clinical diagnostic laboratory that performs RNA-based predictive diagnostic tests, principally the OncoPrism family (OncoPrism-NSCLC and OncoPrism-HNSCC), which use multidimensional biomarkers and machine learning to predict cancer patient response to immunotherapy before treatment decisions. The company's offering is anchored by a proprietary Health Expression Models database of immune cell gene expression profiles and validated through the PREDAPT clinical trial across 11 solid tumor indications with 24+ healthcare system partners.

Is Cofactor Genomics a public or private company?

Cofactor Genomics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Cofactor Genomics founded?

Cofactor Genomics was founded in 2008. It employs 11 to 50 people.

Where is Cofactor Genomics based?

Cofactor Genomics is headquartered in Saint Louis, United States, in the North America region.

How does Cofactor Genomics make money?

Two revenue lines are on record. Diagnostic Laboratory Services are the primary driver. The others are clinical Trial Services.

Who are Cofactor Genomics's main competitors?

Direct peers on record are Oncocyte, Personalis, Caris Life Sciences, NanoString Technologies (Bruker) and Adaptive Biotechnologies. Broad incumbents are Guardant Health, Foundation Medicine (Roche), Natera, NeoGenomics and Exact Sciences.

Does Cofactor Genomics have an API?

No public API is recorded for Cofactor Genomics.

What industry is Cofactor Genomics in?

Cofactor Genomics's product category is Clinical Molecular Diagnostics. Its primary akta.pro industry code is HLAFAMAE, Molecular Diagnostics & Genomics Laboratories, with a secondary code of HLAAAMAJ, Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics). Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business Wire BlogVeteran Oncologist and Cancer Center Leader Dr. Howard Bailey Joins Cofactor Genomics as Chief Medical OfficerCofactor Genomics appointed Howard Bailey, former UW Carbone Cancer Center director, as Chief Medical Officer. He will guide clinical strategy for OncoPrism, an RNA-based predictive test for immunotherapy, with priorities including evidence generation and payer engagement. The company is expanding access and clinical evidence across cancer indications.GlobeNewswireFrom $54B to $85B: A Promising Decade for North America IVDThe North America in-vitro diagnostics market was valued at USD 56.91 billion in 2026 and is projected to reach USD 85.21 billion by 2034, growing at a CAGR of 5.23%, driven by AI integration, molecular diagnostics, and point-of-care testing expansion. Key recent developments include Biocartis collaborating with Mayo Clinic in January 2026 for accelerated breast cancer testing, Cofactor Genomic receiving investments from Labcorp and Ascension Ventures in December 2025, and Freenome partnering with Roche to commercialize cancer screening technology outside the US. Quest Diagnostics announced plans to acquire LifeLabs for CAD 1.35 billion to bolster testing capacity, while the US continues leading the market with FDA approvals for at-home PCR tests and Canada expanding rare-disease screening recommendations to 54 conditions.GenomeWebIn Brief This Week: Cofactor Genomics, Biocartis, Caris Life Sciences, MoreLaboratory Corporation of America and Ascension Ventures have made strategic investments of undisclosed size in St. Louis-based Cofactor Genomics, a developer of RNA-based diagnostic tests. The funding is intended to accelerate the nationwide expansion of Cofactor's OncoPrism assay, which uses tumor RNA measurements combined with machine learning to predict patient response to immune checkpoint inhibitors.BioSpaceCofactor Genomics Advances Predictive Cancer Diagnostics With Landmark OncoPrism-NSCLC StudyCofactor Genomics announced results from the PREDAPT NSCLC trial validating its OncoPrism-NSCLC test, which evaluated 1,487 patient samples across four independent cohorts to predict immunotherapy response in non-small cell lung cancer patients. The test demonstrated a two to three-fold improvement in overall response rate, progression-free survival, and overall survival compared to lower-scoring groups, while outperforming the current standard PD-L1 TPS biomarker. OncoPrism-NSCLC uses RNA extracted from standard biopsy samples and is already commercially launched, CAP-accredited, and Medicare-approved.Business Wire BlogCofactor Genomics Advances Predictive Cancer Diagnostics With Landmark OncoPrism-NSCLC StudyCofactor Genomics announced results from the PREDAPT NSCLC trial validating their OncoPrism-NSCLC test, which predicts which late-stage non-small cell lung cancer patients are likely to benefit from immune checkpoint inhibitor therapy. The study evaluated 1,487 patient samples across four independent cohorts and demonstrated that OncoPrism-NSCLC outperformed the current standard PD-L1 TPS biomarker, with patients identified as 'OncoPrism High' showing a two to three-fold improvement in response rates and survival measures. The test, already launched in Cofactor's CAP-accredited, CLIA-certified laboratory, uses RNA from standard tumor biopsy samples and was validated as a predictive biomarker of ICI benefit specifically.American City Business JournalsCofactor Genomics lands investments from Labcorp, AscensionCofactor Genomics, a St. Louis-based biotech company, has secured new funding from Labcorp and Ascension's venture capital arm to expand its technology for predicting which cancer patients will respond best to immunotherapy treatments. The investment from the major lab services business and health system venture arm will support the company's growth in precision oncology diagnostics. This funding round represents continued investor interest in personalized cancer treatment technologies that could improve patient outcomes.Pulse 2.0Cofactor Genomics Secures Strategic Investment From Labcorp And Ascension VenturesCofactor Genomics secured strategic investments from Labcorp and Ascension Ventures to accelerate the nationwide expansion of its OncoPrism immunotherapy response diagnostic. The funding aims to broaden patient access across U.S. cancer care networks by leveraging Labcorp's national laboratory infrastructure and Ascension Ventures' reach across 13 health systems.MarketScreenerCofactor Genomics announces strategic investment by LabCorp and Ascension VenturesCofactor Genomics has announced a strategic investment secured by LabCorp and Ascension Ventures. This financial backing supports the company's ongoing operations within the healthcare diagnostics sector. The article provides no further details on the transaction value or specific strategic implications.MarketScreenerCofactor Genomics, Inc. announced that it has received $4.489513 million in funding from Labcorp Holdings Inc., Ascension Ventures, LLCCofactor Genomics, Inc. announced it has received $4.489513 million in funding from Labcorp Holdings Inc. and Ascension Ventures, LLC. The investment provides capital support to the biotech company Cofactor Genomics. No forward-looking statements or broader context about the use of proceeds were provided in the announcement.Business Wire BlogCofactor Genomics Announces Strategic Investment by Labcorp and Ascension Ventures to Fuel Expansion of Its OncoPrism® Immunotherapy Diagnostic Across U.S. Cancer Care NetworksCofactor Genomics announced strategic investments from Labcorp and Ascension Ventures to accelerate nationwide expansion of its OncoPrism immunotherapy-response diagnostic across U.S. cancer care networks. The OncoPrism platform uses machine-learning analysis of tumor RNA to predict patient response to immune checkpoint inhibitor therapy, with performance validated in the national PREDAPT trial. Proceeds will support clinical evidence generation, health-system integration, and scaling of commercial and lab operations to meet growing demand in U.S. oncology markets.